Ultragreen Ai Ltd
Company Profile
Business description
Ultragreen Ai Ltd is engaged in the sales of Indocyanine Green (ICG) pharmaceutical products and cardiology Picture Archiving and Communication System (PACS) software and associated products and services. It provides a fluorescence imaging ecosystem designed to support surgeons with real-time perfusion data and visualization capabilities. The company is organised into business units based on its products and services and operates in (a) the Diagnostic Green (DxG) - Americas segment; (b) the DxG - Rest of the World segment; and (c) the UltraLinQ segment. The company generates the maximum of its revenue from the the DxG - Rest of the World segment, which focuses on the sales of ICG vials and related pharmaceutical products.
Contact
463 MacPherson Road
M463
Singapore368181
SGPT: +65 98172903
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 December 2026
Employees
101
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.70 | 33.00 | 0.36% |
| CAC 40 | 8,425.13 | 0.00 | 0.00% |
| DAX 40 | 24,702.24 | 547.77 | 2.27% |
| Dow JONES (US) | 49,447.43 | 868.71 | 1.79% |
| FTSE 100 | 10,667.63 | 77.64 | 0.73% |
| HKSE | 26,160.33 | 233.93 | -0.89% |
| NASDAQ | 24,468.48 | 365.78 | 1.52% |
| Nikkei 225 | 58,475.90 | 1,042.44 | -1.75% |
| NZX 50 Index | 12,905.67 | 160.39 | -1.23% |
| S&P 500 | 7,126.06 | 84.78 | 1.20% |
| S&P/ASX 200 | 8,946.90 | 36.80 | 0.41% |
| SSE Composite Index | 4,051.43 | 4.12 | -0.10% |